Condition
Alpha Mannosidosis
Total Trials
6
Recruiting
0
Active
0
Completed
4
Success Rate
80.0%-7% vs avg
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
80.0%
-6.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
2 of 4 completed with results
Key Signals
2 with results80% success
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (3)
Trial Status
Completed4
Terminated1
Unknown1
Trial Success Rate
80.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT01891422Completed
Longitudinal Studies of the Glycoproteinoses
NCT00498420CompletedPrimary
The Natural History of Alpha-Mannosidosis
NCT01268358Phase 1CompletedPrimary
Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis
NCT01043640Phase 2Completed
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
NCT00668564Phase 2Terminated
Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism
NCT01285700Phase 2UnknownPrimary
Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis
Showing all 6 trials